Olopade Olufunmilayo (38076873/2023)

Paper Title

Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.

Pubmed ID

38076873

Date

2024/02/24

Member Group

SPARCo Nigeria

Member Name

Olopade Olufunmilayo

First Author

Florencia P Madorsky Rowdo

First Author Affiliation

Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York, NY10021

Last Author

Jill Bargonetti

Last Author Affiliation

The Department of Biological Sciences Hunter College, Belfer Building, City University of New York, New York, NY10021